RecruitingPhase 3NCT07210515
Rare condition
Triple A syndrome
13
studies recruiting now
as of 7 Sept 2026
93
studies registered in total
as of 7 Sept 2026
6
countries with a recruiting site
as of 7 Sept 2026
22 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT02302742
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
RecruitingPhase 1NCT07718997
A Multiple Baseline Feasibility Trial of Social Management Training for People With Sex Chromosome Aneuploidies
RecruitingNot applicableNCT07713641
Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function
RecruitingPhase 1NCT06419634
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 13 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Triple A syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Triple A syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (TRAPPC11, AAAS, GMPPA).
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).